Conflicts of interest Stiefel International R&D financially supported this trial and the investigators for the duration of the trial. They also supplied the preliminary draft of this paper.
A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo
Article first published online: 22 APR 2009
© 2009 The Authors. Journal Compilation © 2009 British Association of Dermatologists
British Journal of Dermatology
Volume 161, Issue 4, pages 910–917, October 2009
How to Cite
Bakis-Petsoglou, S., Le Guay, J.L. and Wittal, R. (2009), A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. British Journal of Dermatology, 161: 910–917. doi: 10.1111/j.1365-2133.2009.09252.x
All authors were clinical investigators for the duration of the trial.
This paper does not imply that the views expressed are endorsed by the company that funded the trial.
The results of the trial were presented at the Australasian College of Dermatologists’ 35th Annual Scientific Meeting, Melbourne, May 2002.
- Issue published online: 22 SEP 2009
- Article first published online: 22 APR 2009
- Accepted for publication 30 March 2009
- clinical trial;
- narrowband ultraviolet B;
- randomized controlled trial;
Background Pseudocatalase cream in conjunction with narrowband ultraviolet B (NB-UVB) has previously been reported to result in repigmentation of vitiliginous skin.
Objectives The purpose of this 24-week, double-blind, placebo-controlled, randomized, single-centre trial was to assess the efficacy of pseudocatalase cream and NB-UVB vs. placebo and NB-UVB for the treatment of vitiligo.
Methods Patients with active vitiligo on their face and/or hands applied either pseudocatalase cream or placebo to their whole body, twice daily for 24 weeks. NB-UVB therapy was administered three times a week for the duration of the trial. Efficacy was assessed primarily by digital image analysis of photographs.
Results Thirty-two patients were randomized to either the pseudocatalase arm (n = 14) or placebo (n = 18). Between-group analysis did not show a statistically significant improvement in percentage area affected in the pseudocatalase cream group when compared with placebo. However, a statistically significant improvement was found within each group by week 12, which was maintained throughout the study.
Conclusions NB-UVB treatment is a moderately effective treatment for vitiligo. Pseudocatalase cream does not appear to add any incremental benefit to NB-UVB alone.